Drug Profile
GSK 1536489A
Alternative Names: FluLaval; FluLaval trivalent; FluLaval-YB; FluSF; Fluviral; Fluviral-S-F; Fluviral-S/F; GSK-1536489A; GSK-1557482A; Influenza vaccine split virion inactivated - GSK; SPD-707Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator ID Biomedical Corporation
- Developer Folia Biotech; GSK; ID Biomedical Corporation; Pan-Provincial Vaccine Enterprise
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 02 Oct 2019 Safety and immunogenicity data from a phase I trial in Influenza virus infections presented at the IDWeek (IDW-2019)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention, Adjuvant therapy) in Canada (IM, Injection)
- 01 Apr 2014 Phase-I clinical trials in Influenza virus infections (adjuvant therapy, prevention) in Canada (IM)